Literature DB >> 5554937

Plasma DOPA response to levodopa administration in man: effects of a peripheral decarboxylase inhibitor.

D L Dunner, H K Brodie, F K Goodwin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5554937     DOI: 10.1002/cpt1971122part1212

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  14 in total

Review 1.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

Review 2.  Antiparkinsonian drugs: pharmacological and therapeutic aspects.

Authors:  D B Calne; J L Reid
Journal:  Drugs       Date:  1972       Impact factor: 9.546

3.  [Differential treatment of Parkinson's disease, with special reference to the possibility of iatrogenic disorders (author's transl)].

Authors:  W Gehlen
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1974-04-09

Review 4.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of levodopa in parkinson's disease.

Authors:  J R Bianchine; G M Shaw
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 6.  Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

7.  Systemic activity of orally administered L-dopa in the elderly Parkinson patient.

Authors:  M A Evans; E J Triggs; G A Broe; N Saines
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

8.  Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease.

Authors:  Markos Poulopoulos; Cheryl Waters
Journal:  Core Evid       Date:  2010-07-27

9.  Intestinal absorption of levodopa in man.

Authors:  U Gundert-Remy; R Hildebrandt; A Stiehl; E Weber; G Zürcher; M Da Prada
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa.

Authors:  D B Calne; J L Reid; S D Vakil; S Rao; A Petrie; C A Pallis; J Gawler; P K Thomas; A Hilson
Journal:  Br Med J       Date:  1971-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.